{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"8.3","value":"4.7"},{"groupId":"OG001","lowerLimit":"1.6","upperLimit":"6.0","value":"3.0"},{"groupId":"OG002","lowerLimit":"1.9","upperLimit":"5.5","value":"3.7"},{"groupId":"OG003","lowerLimit":"1.9","upperLimit":"3.8","value":"2.9"}]}],"title":"RECIST v1.1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"13.8","value":"4.9"},{"groupId":"OG001","lowerLimit":"1.9","upperLimit":"13.7","value":"4.5"},{"groupId":"OG002","lowerLimit":"2.8","upperLimit":"8.2","value":"5.5"},{"groupId":"OG003","lowerLimit":"2.0","upperLimit":"14.5","value":"3.8"}]}],"title":"irRECIST"}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"67"},{"groupId":"OG003","value":"38"}],"units":"Participants"}],"description":"PFS was defined as the time from initiation of study intervention to first documentation of tumor progression or to death due to any cause, whichever occurred first. PFS was analyzed by the Kaplan-Meier approach for each tumor type. As this outcome measure was a secondary endpoint defined in the protocol to investigate preliminary signal of efficacy, the results were analyzed and are reported for Part 1 dose-escalation groups combined to provide more statistically meaningful results, instead of results analyzed by dose level with very limited number of participants in each group.","dispersionType":"95% Confidence Interval","groups":[{"description":"This was a combined group of PF-06801591 0.5, 1, 3, and 10 mg/kg (IV) in Part 1. Participants received PF-06801591 0.5, 1, 3, or 10 mg/kg IV every 3 weeks for 21-day cycles. (up to a maximum of 233 weeks).","id":"OG000","title":"Part 1: PF-06801591 0.5-10 mg/kg (Intravenously [IV])"},{"description":"Participants received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 419 days)","id":"OG001","title":"Part 1: PF-06801591 300 mg (Subcutaneously [SC])"},{"description":"Participants with NSCLC received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 851 days)","id":"OG002","title":"Part 2: PF-06801591 300 mg (SC) for NSCLC"},{"description":"Participants with UC received PF- 06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 841 days)","id":"OG003","title":"Part 2: PF-06801591 300 mg (SC) for UC"}],"paramType":"MEDIAN","populationDescription":"Analysis population included all the randomized participants who received at least 1 dose of study medication, had measurable disease baseline assessment (within 28 days prior to study entry) and at least 1 post baseline assessment or disease progression, global deterioration of health status, or death.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of treatment (maximum of 1606 days)","title":"Progression-Free Survival (PFS) Based on RECIST Version 1.1 and irRECIST - Part 1 and Part 2","type":"SECONDARY","unitOfMeasure":"Months"}